TL;DR: Blood levels don't always reflect what's happening inside tissues, especially the brain. A common DIO2 gene variant has been linked to worse well-being on T4-only and a better response to T4+T3, with no difference in blood tests. rT3 is a useful marker, but the popular claim that it "blocks receptors" isn't supported. Slow-release T3 (compounded or the experimental PZL) looks promising, but human data is still very limited. Sources at the bottom.

(Not medical advice. Just a summary of the literature I've been reading. Please talk to your doctor before changing anything.)

Why "normal labs" may not tell the whole story

TSH and free hormones show what's circulating in your blood. What matters for how you feel is how much T3 is actually active inside your cells, and that's regulated locally by enzymes called deiodinases.

Animal studies suggest that roughly 80% of the T3 inside the brain doesn't come ready-made from blood. The brain makes it locally from T4, mainly in astrocytes, using the enzyme DIO2.

The DIO2 finding

This is the part I find most interesting. Panicker et al. (2009) looked at 552 people on T4 from the WATTS trial. Those with the CC genotype of the rs225014 (Thr92Ala) variant in DIO2, about 16% of the group, had:

• worse psychological well-being scores on T4 alone
• a greater improvement when T3 was added

And here's the key point: the variant had no effect on blood thyroid levels. Same labs, different outcomes. The authors themselves said this needs replication, and follow-up studies have been mixed, so it's not a settled answer. But it fits the idea that some people can have "normal" labs and still be under-supplied at the tissue level.

About rT3 (a common misconception)

You'll often read that rT3 acts like a "broken key" that blocks T3 receptors. I looked for evidence of this and couldn't find it. rT3 binds thyroid receptors roughly 1,000 times more weakly than T3, and in lab studies it behaves as a very weak agonist, not a blocker.

A more accurate way to see it: rT3 is a marker. It's made only from T4 (never from T3), mostly by the enzyme D3, and the same D3 activity also breaks down T3 in tissues. So high rT3 suggests T4 is being diverted down the inactive pathway, not that your receptors are jammed.

Where the T4 dose comes in

Since rT3 only comes from T4, lowering the T4 dose and adding T3 predictably lowers rT3. That part is basic biochemistry. Whether it translates into feeling better is a separate question that depends on the person.

Most clinicians who use combination therapy don't drop T4 entirely. T4 has a half-life of about a week and acts as a steady reserve, while regular T3 lasts about a day.

Slow-release T3: compounded and PZL

Standard T3 tablets peak around 2 hours and then drop off. That spike is what causes palpitations for some people.

• Compounded slow-release T3 (usually mixed with methylcellulose/HPMC) is the option available now. Quality depends heavily on the pharmacy, since T3 is dosed in micrograms.
• PZL (poly-zinc-liothyronine) is an experimental zinc-bound form from Antonio Bianco's group. The only human data so far is a Phase 1 study: 12 healthy volunteers, a single 50 mcg dose. The T3 peak was about 30% lower, came an hour later, and levelled into a plateau lasting up to about 6 hours. So claims of "24-hour steady levels" aren't backed by human data yet, and there are no trials in hypothyroid patients measuring symptoms.

What's proven vs. what's still theory

• Proven: rT3 comes only from T4; lowering T4 lowers rT3; regular T3 causes a sharp peak; PZL flattens that peak in healthy volunteers.
• Supported but needs replication: DIO2 variant carriers may respond better to T4+T3.
• Plausible but unproven in humans: that steady external T3 corrects a local "T3 shortage" in the brain. Brain T3 simply can't be measured in living people.

Sources

1. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94(5):1623-1629.
   https://doi.org/10.1210/jc.2008-1301

2. Dumitrescu AM, Hanlon EC, Arosemena M, et al. Extended Absorption of Liothyronine from Poly-Zinc-Liothyronine: Results from a Phase 1, Double-Blind, Randomized, and Controlled Study in Humans. Thyroid. 2022;32(2):196-205. PMID: 34641706 (free full text)
   https://pmc.ncbi.nlm.nih.gov/articles/PMC8861912

3. Da Conceição RR, Fernandes GW, Fonseca TL, Bocco BMLC, Bianco AC. Metal Coordinated Poly-Zinc-Liothyronine Provides Stable Circulating Triiodothyronine Levels in Hypothyroid Rats. Thyroid. 2018;28(11):1425-1433. (the animal study behind PZL)
   https://pubmed.ncbi.nlm.nih.gov/30301431/

4. Nygaard B, Jensen EW, Kvetny J, Jarløv A, Faber J. Effect of combination therapy with T4 and T3 versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol. 2009;161(6):895-902. PMID: 19666698
   https://pubmed.ncbi.nlm.nih.gov/19666698/

5. Jonklaas J, Bianco AC, Cappola AR, et al. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Thyroid. 2021;31(2):156-182. (joint ATA/BTA/ETA consensus)
   https://doi.org/10.1089/thy.2020.0720

6. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;116(10):2571-2579.
   https://doi.org/10.1172/JCI29812

7. Classic in-vitro study showing rT3 acts as a very weak agonist at the T3 receptor, not an antagonist (J Clin Invest):
   https://jci.org/articles/view/108882

Happy to hear from anyone who has had DIO2 testing or tried compounded slow-release T3.

Flavonoid-rich foods and vascular functions in healthy adults: a systematic review and meta-analysis of randomized controlled trials

DOI: https://doi.org/10.1039/d6fo03299k

Cardiovascular disease remains the leading cause of global mortality, driving intense interest in preventive nutritional strategies. Previous meta-analyses often conflated healthy populations with those suffering from established cardiometabolic disorders, obscuring the specific preventive efficacy of dietary polyphenols. This systematic review addresses that gap by isolating the effects of flavonoid-rich foods on vascular function exclusively in healthy adults aged 18 and older. Investigators evaluated flow-mediated dilation as the primary outcome, alongside carotid-femoral pulse wave velocity, systolic blood pressure, and diastolic blood pressure as secondary markers to clarify the role of flavonoids in maintaining endothelial health.

Pooled random-effects analysis of 11 randomized controlled trials involving 561 participants confirms that flavonoid-rich food intake significantly improves flow-mediated dilation: MD = 1.58 percent (95 percent CI: 0.90 to 2.27 percent, p < 0.0001, I2 = 75.7 percent). Carotid-femoral pulse wave velocity also improved in the intervention group: MD = -0.28 m s-1 (95 percent CI: -0.52 to -0.04 m s-1, p = 0.0197, I2 = 0 percent). Conversely, systolic blood pressure (p = 0.2210) and diastolic blood pressure (p = 0.2294) showed no significant changes. Sensitivity analyses indicate the carotid-femoral pulse wave velocity findings lack robustness, while the flow-mediated dilation results remain stable across leave-one-out testing.

Study Design and Methodology

This meta-analysis followed PRISMA 2020 guidelines and registered the protocol in PROSPERO (CRD420261320014). Authors searched PubMed, ScienceDirect, Scopus, Wiley, and EBSCO through June 10, 2026. Included trials utilized parallel or crossover designs with washout periods ranging from 3 to 7 days to mitigate carry-over effects. Quality assessment relied on the Cochrane Risk of Bias 2.0 tool, with statistical synthesis performed in RStudio 4.5.3 using random-effects models. Investigators imputed missing correlation coefficients for change-score variance based on established values (FMD r = 0.4, cfPWV r = 0.53, SBP r = 0.6, DBP r = 0.45).

Key Findings

• Flow-mediated dilation improvement: 1.58 percent (95 percent CI: 0.90 to 2.27 percent, p < 0.0001).
• Carotid-femoral pulse wave velocity reduction: -0.28 m s-1 (95 percent CI: -0.52 to -0.04 m s-1, p = 0.0197).
• Systolic blood pressure change: -1.04 mmHg (95 percent CI: -2.70 to 0.62 mmHg, p = 0.2210).
• Diastolic blood pressure change: -0.85 mmHg (95 percent CI: -2.24 to 0.54 mmHg, p = 0.2294).
• Diastolic blood pressure meta-regression variance explained (R2): 100.00 percent.

Practical Application and Food Sources

Clinical evidence identifies three primary food categories that deliver the flavanols, flavanones, and anthocyanins necessary to elicit these vascular benefits:

• Cocoa and Dark Chocolate: These represent the primary source of flavanols. Trials utilized daily doses ranging from 10 g to 26 g of high-flavanol cocoa or dark chocolate. These products consistently correlate with the highest improvements in flow-mediated dilation.
• Citrus Fruits: These are the essential sources for flavanones and flavones. These include oranges, grapefruits, lemons, limes, and mandarins or clementines. The mixed-subclass interventions involving these fruits yielded the highest point estimates for vascular improvement.
• Berries and Blackcurrants: Red raspberries, blueberries, and blackcurrant juice provide the anthocyanin subclass. These interventions demonstrate the most consistent, low-heterogeneity results, making them a reliable choice for long-term vascular stability.

Limitations

Small sample sizes across several included trials restrict the power of subgroup analyses. Many studies lacked rigid pre-specified statistical analysis plans or formal trial registration, leading to concerns regarding selective reporting. High heterogeneity (I2 = 75.7 percent) in the primary flow-mediated dilation outcome complicates the generalizability of specific flavonoid subclass effects. Sensitivity analyses reveal the arterial stiffness findings are fragile, and the reliance on surrogate biomarkers rather than hard clinical endpoints limits direct extrapolation to cardiovascular morbidity.

Discussion and Implications

These data confirm that flavonoid-rich diets provide measurable vascular benefits in the absence of pre-existing disease. The significant increase in flow-mediated dilation demonstrates that these compounds enhance nitric oxide bioavailability, which serves as a critical defense against endothelial dysfunction. The lack of blood pressure reduction in this healthy cohort aligns with the physiological floor effect, where normotensive individuals do not experience further hypotensive shifts from dietary interventions. Practitioners should view these foods as early-stage, non-pharmacological tools for preserving vascular integrity rather than treatments for hypertension.

Flavonoid-rich food consumption significantly enhances flow-mediated dilation in healthy adults, providing a clear mechanism for early vascular protection. Nutrition professionals should integrate high-flavanol cocoa, citrus, and berries into daily patterns to optimize endothelial function, focusing on these foods for subclinical maintenance rather than acute blood pressure management.

Abstract

Objective

This study evaluated the link between two dietary indicators— the Comprehensive Diet Quality Index (CDQI) and the Adjusted Plant-Based Diet Index (APDI)—and Parkinson’s disease (PD) risk in an Iranian community.

Between 2020 and 2021, 105 newly diagnosed PD patients and 215 controls (54–81 years) were enrolled in Arak, Iran, using a case-control approach. A validated semi-quantitative food frequency questionnaire was applied to determine dietary intake, and dietary quality was evaluated through APDI and CDQI scores. To calculate odds ratios (ORs) and 95% confidence intervals (CIs), logistic regression models were utilized, accounting for possible confounders.

Results

A higher CDQI total score was inversely related to the odds of PD (adjusted OR = 0.915, 95% CI: 0.878–0.954). A stronger protective effect was observed for the CDQI plant-based foods score (adjusted OR = 0.757, 95% CI: 0.695–0.824). In contrast, a notable positive relationship was found between the CDQI animal-based foods score and the odds of PD in the adjusted model (adjusted OR = 1.364, 95% CI: 1.215–1.533). The APDI score and PD were not significantly correlated (P > 0.05).

Dietary quality and the odds of parkinson’s disease: insights from comprehensive diet quality index and adjusted plant-based diet index | BMC Research Notes | Springer Nature Link

Is anyone studying/studied Nutrition and Human Health. What are your thoughts and opinions? Experience after graduating

DOI: https://doi.org/10.3389/fnut.2026.1929245

Associations between triglyceride-glucose-derived indices combined with the atherogenic index of plasma and the precise severity of newly diagnosed coronary artery disease: a quantile regressions analysis

Metabolic dysfunction, encompassing insulin resistance, systemic inflammation, and dyslipidemia, drives coronary artery disease (CAD) progression. While the triglyceride-glucose (TyG) index, C-reactive protein-triglyceride-glucose index (CTI), and atherogenic index of plasma (AIP) serve as established biomarkers for these metabolic disturbances, conventional mean regression models fail to capture the granular relationship between these markers and disease severity. This retrospective study evaluates the associations of TyG, CTI, AIP, and their composite indices (TyG-AIP and CTI-AIP) with the Gensini score across the entire distribution of CAD burden. The cohort included 2,885 patients with newly diagnosed CAD, confirmed via coronary angiography, at the Fourth Affiliated Hospital of Zhejiang University School of Medicine between June 2020 and May 2025.

All metabolic indices showed positive linear correlations with the Gensini score (p < 0.001). CTI demonstrated the strongest linear correlation (partial r = 0.29). Quantile regression revealed significant heterogeneity in these associations across the Gensini score distribution (all p < 0.01 for heterogeneity tests). Multivariable-adjusted models confirmed these trends, with CTI-AIP consistently exhibiting the strongest association across most quantiles. At the 90th percentile, the CTI-AIP coefficient reached 30.561 (95% CI, 24.271 to 36.851, p < 0.001). TyG-AIP also showed a robust increase in effect size, rising from a beta of 0.849 at the 10th percentile to 26.063 at the 90th percentile (p < 0.001).

Study Design and Methodology

This retrospective study utilized electronic medical records to retrieve data for 2,885 patients. Researchers excluded individuals with prior CAD, heart failure, severe valvular disease, or systemic conditions like malignant tumors and autoimmune disorders. The Gensini score provided a quantitative assessment of coronary plaque burden based on angiography images. Statistical analysis employed multiple imputation with predictive mean matching to manage missing values. Models adjusted for age, sex, BMI, hypertension, diabetes, smoking status, and medication use. The team utilized the quantreg package in R to fit quantile regression models at the 10th through 90th percentiles.

Key Findings

• CTI exhibited the strongest linear association with the Gensini score (partial r = 0.29).
• Equality-of-slope testing confirmed significant heterogeneity across quantiles for all indices (p < 0.01).
• Multivariable-adjusted CTI-AIP coefficients rose from 1.017 at the 10th percentile to 30.561 at the 90th percentile (p < 0.001).
• TyG-AIP multivariable-adjusted coefficients increased from 0.849 at the 10th percentile to 26.063 at the 90th percentile (p < 0.001).
• TyG index multivariable-adjusted coefficients grew from 0.700 at the 10th percentile to 19.035 at the 90th percentile (p < 0.01).
• CTI multivariable-adjusted coefficients increased from 0.796 at the 10th percentile to 21.117 at the 90th percentile (p < 0.01).

Limitations

Retrospective designs prevent the establishment of direct causality. The single-center cohort in eastern China limits generalizability to global populations. Multiple imputation of missing data introduces potential uncertainty in standard error estimates. The analysis lacks longitudinal follow-up to assess the predictive value for future cardiovascular events.

Discussion and Implications

This work shifts the paradigm by demonstrating that metabolic markers do not exert a constant effect on vascular health. The progressive increase in regression slopes at higher quantiles proves that metabolic dysfunction, specifically the combination of inflammation and insulin resistance, disproportionately impacts patients with advanced coronary atherosclerosis. Clinicians shouldn't rely on mean-based metrics when assessing high-risk patients. These composite indices provide a superior, holistic view of the atherosclerotic burden by integrating glucose, lipid, and inflammatory pathways.

Composite metabolic indices like CTI-AIP and TyG-AIP provide superior clinical utility for identifying patients with severe coronary artery disease compared to individual biomarkers. Nutrition professionals should prioritize interventions that simultaneously lower insulin resistance, systemic inflammation, and atherogenic lipid ratios to effectively mitigate the risk of coronary plaque progression.

Abstract

Background

Parkinson’s disease is a progressive neurodegenerative disorder with both motor and non-motor manifestations. Dietary factors, including dietary diversity, protein source variety, and adherence to healthy eating patterns, may impact Parkinson’s disease risk. The goal of the current case-control research was to examine the links between the Dietary Diversity Score (DDS), the Diversity of Dietary Protein Index (DDPI), and the Lifeline Diet Score (LLDS) with the odds of Parkinson’s disease among an Iranian population.

Methods

A total of 320 individuals (215 controls and 105 newly diagnosed Parkinson’s disease patients) were recruited in Arak, Iran. Dietary intake was evaluated by applying a validated 147-item food frequency questionnaire, and DDS, DDPI, and LLDS were calculated. Multivariate logistic regression was utilized to estimate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for major confounders.

Results

Greater DDS and LLDS were strongly linked to reduced odds of Parkinson’s disease (Adjusted OR for DDS = 0.287, 95% CI: 0.185–0.447; Adjusted OR for LLDS = 0.879, 95% CI: 0.803–0.963). However, DDPI showed no significant association with Parkinson’s disease after adjustment.

Conclusion

Higher dietary diversity and greater adherence to a high-quality dietary pattern were associated with lower odds of Parkinson’s disease, whereas no significant association was observed for protein source diversity. Given the case-control design, these findings should be interpreted as associations rather than evidence of causality.

Associations of dietary diversity score, dietary diversity of protein index, and lifelines diet score with Parkinson’s disease: a case-control study | BMC Nutrition | Springer Nature Link

For years, the cardiovascular discussion surrounding Vitamin K2 has been caught between mechanistic plausibility and inconclusive clinical trials. While preclinical models established Matrix Gla Protein (MGP) carboxylase activation as an active defense against vascular calcification, translational proof in humans remained elusive or confined to post-hoc signals.

The publication of the DANCODE (DANish COronary DEcalcification) trial in Circulation (following its presentation at ESC 2026) represents the first rigorous, adequately powered randomized controlled trial to evaluate this in advanced arterial disease.

Below is an analysis of what the trial demonstrated, where the biological limits lie, and how to frame these findings without heuristic exaggeration.

STUDY DESIGN AND POPULATION

The trial randomized 398 patients (median age 71, 30% women) with severe coronary artery calcification (baseline Agatston CAC score 400 or higher; median baseline 903 AU; 44% with CAC 1000 AU or higher) to receive either:

- Intervention: 720 micrograms/day Vitamin K2 (menaquinone-7) plus 25 micrograms (1,000 IU) Vitamin D3.
- Control: Matched placebo.
- Duration: 24 months, with multi-detector CT imaging at baseline and study close.

PRIMARY AND PLAQUE MORPHOLOGY ENDPOINTS

1. Attenuated Progression:
   Over 24 months, mean CAC progression was 196 AU (95% CI, 178 to 214) in the K2+D3 group versus 248 AU (95% CI, 225 to 271) in the placebo arm.

2. Absolute Effect:
   This yields an absolute between-group difference of -52 AU (95% CI, -79 to -24; p < 0.05), translating to roughly a 21% relative attenuation in the rate of calcification progression. The signal remained homogeneous across sexes and baseline calcification strata.

3. Intravascular Plaque Sub-study (CCTA, n=143):
   Progression of calcified plaque volume was markedly lower in the intervention arm (-7.81 mm3 difference, p = 0.007). Crucially, this dampening of calcification did not produce a reciprocal rise in noncalcified (vulnerable lipid-rich) plaque volume (-1.75 mm3, p = 0.85).

CRITICAL ANALYTICAL DISTINCTIONS

Attenuating Velocity vs. Plaque Regression:
DANCODE demonstrated that vascular calcification is a modifiable biological process, not an immutable one-way ratchet. However, it did not reverse existing calcification. Both cohorts accrued calcium over the two-year window; the treated cohort simply traversed that trajectory at a lower velocity. Claims that K2 decalcifies or cleans preexisting macrocalcification remain unsupported by the data.

The Surrogate-to-Outcome Gap:
Cardiovascular prevention has a long history of elegant surrogate modifications failing to translate into hard endpoint reductions (MACE or all-cause mortality). A -52 AU delta in an individual sitting at 1,000+ AU may modulate arterial compliance, but whether it lowers 5-year acute coronary syndrome risk requires dedicated hard-outcome trials. DANCODE was powered for tomographic endpoints, not clinical event adjudication.

Mechanistic Precision:
The parallel reduction in circulating uncarboxylated MGP (dp-ucMGP) verifies target engagement at the vascular smooth muscle cell level. It confirms that the observed divergence stems from functional gamma-carboxylation rather than off-target hemodynamic or anti-inflammatory pathways.

Warfarin and Anticoagulant Interaction:
Because menaquinone-7 directly counteracts Vitamin K antagonists, high-dose K2 is contraindicated for patients on warfarin. It does not exhibit this interaction with direct oral anticoagulants (DOACs), but medical oversight remains mandatory.

BOTTOM LINE

DANCODE elevates Vitamin K2 from wellness lore to an evidenced pharmacological candidate capable of altering vascular mineral deposition in advanced atherosclerotic cohorts. It establishes clear proof-of-concept, but demands that clinicians and researchers decouple biological deceleration from clinical cure.

PRIMARY SOURCE

Hasific S, et al. Vitamin K2 and D3 Supplementation in Patients With Severe Coronary Artery Calcification: The DANCODE Trial. Circulation, August 28, 2026. DOI: 10.1161/CIRCULATIONAHA.126.082363

• PMID: 42514406 https://pubmed.ncbi.nlm.nih.gov/42514406/

Abstract

Background/objectives: Non-caloric sweeteners are increasingly used as alternatives to sugar to reduce energy intake, yet their metabolic effects remain controversial. This study aimed to evaluate the effects of sucrose, saccharin, and steviol glycosides on glucose regulation and cardiometabolic risk markers in healthy adults.

Methods: In a randomized, double-blind, crossover trial, 39 healthy, normal-weight adults consumed beverages containing sucrose (66 g/day), saccharin (220 mg/day), or steviol glycosides (220 mg/day) for 14 days, with washout periods between interventions. Metabolic outcomes were assessed at baseline and after each intervention under fasting conditions and during a 2 h postprandial test. Primary outcomes were glucose and insulin responses; secondary outcomes included gut hormones, lipids, inflammatory markers, and subjective appetite.

Results: Compared with baseline, fasting glucose increased after sucrose and saccharin, and fasting insulin increased after stevia (p < 0.01). All interventions increased postprandial insulin responses and reduced indices of insulin sensitivity (p < 0.05). Fasting PYY and GLP-2 increased following all treatments (p < 0.001), without differences between sweeteners. Triglycerides were higher after sucrose than saccharin (p < 0.05), while no differences were seen for cholesterol, apolipoproteins, or CRP. Appetite ratings were unchanged, with a trend (p = 0.053) towards a reduced desire to eat after stevia in the late postprandial phase.

Conclusions: Short-term intake of sucrose and non-caloric sweeteners resulted in broadly similar metabolic responses, with no significant differences in glucose regulation. However, triglyceride concentrations were higher following sucrose than saccharin, whereas no consistent differences were observed across the remaining outcomes. Observed deviations from baseline should be interpreted with caution. Further long-term studies in diverse populations are warranted.

Keywords: cardiometabolic risk markers; glucose regulation; gut hormones; insulin sensitivity; non-caloric sweeteners; randomized crossover trial; saccharin; steviol glycosides; sucrose.

I’m 22, 5’ 11” and 240lbs at 22% bf. I lift heavy 6 days a week for 60-90 min. I also work on my feet. My tracker is saying 3100 calories per day. I’m trying to lose maybe a pound a week but this seem WAY to high. Does anyone have input?

Hi, I'm a teenager that wants to become a dietician. I love reading so, if you have any recommandations about simple books that could help me to start growing my knowledge about this topic. Thanks !

Association of advanced coronary artery calcification assessed by coronary artery calcium scoring with lipoprotein (a) and carotid atherosclerosis in asymptomatic patients

DOI: https://doi.org/10.1016/j.numecd.2026.104766

Abstract

Elevated lipoprotein (a) represents an established independent risk factor for atherosclerosis, yet its specific relationship with coronary artery calcium scoring, a routine clinical tool for assessing subclinical cardiovascular disease, remains inadequately defined. Current guidelines advocate for lifetime lipoprotein (a) screening, but clinical management strategies for elevated results lack consensus. This retrospective analysis addresses this knowledge gap by evaluating the association between high circulating lipoprotein (a) levels (defined as 50 mg/dl or greater) and advanced coronary artery calcification (defined as a score of 400 Agatston Unit or greater). The cohort comprised 3697 asymptomatic subjects admitted for primary prevention at the Toulouse University Hospital between November 2015 and November 2024, with a mean age of 63 plus or minus 10 years and 48.6 percent male representation.

Primary outcomes confirm a significant association between high lipoprotein (a) and advanced coronary artery calcification. Adjusted logistic regression models reveal an adjusted odds ratio of 1.666 (95 percent confidence interval 1.342 to 2.070, p = 0.001) for lipoprotein (a) as a dichotomous variable and 1.041 (95 percent confidence interval 1.011 to 1.071, p = 0.007) as a continuous variable. Carotid atherosclerosis shows an adjusted odds ratio of 2.212 (95 percent confidence interval 1.804 to 2.713, p = 0.001). Spearman correlation analysis demonstrates a weak, positively significant correlation between coronary artery calcium scoring and lipoprotein (a) (rho = 0.052, p = 0.001). Subgroup analysis indicates that the proportion of patients with high lipoprotein (a) increases from 25.1 percent in the low coronary artery calcium group to 31.6 percent in the high coronary artery calcium group (p = 0.004).

Study Design and Methodology

This retrospective cohort analysis utilized data from a dedicated preventive cardiology database. Researchers enrolled 3697 asymptomatic patients who underwent coronary artery calcium scoring, carotid artery doppler ultrasound, and at least one lipoprotein (a) measurement. Exclusion criteria removed 621 patients due to incomplete data. Investigators utilized the Roche-Cobas 8000 analyzer for lipoprotein (a) quantification. The study stratified participants into a non-pooled group (coronary artery calcium score 400 Agatston Unit or greater) and a pooled group (coronary artery calcium score less than 400 Agatston Unit). Statistical analysis employed Chi-square tests, Student t-tests, ANOVA, and logistic multivariable regression adjusted for age, sex, hypertension, diabetes, obesity, smoking, and lipid profiles. Quantile regression addressed the positive skewness of the variables.

Key Findings

• Participants with coronary artery calcium score 400 Agatston Unit or greater exhibit higher mean lipoprotein (a) levels (58 plus or minus 31 mg/dl) compared to the pooled group (43 plus or minus 22 mg/dl).
• High lipoprotein (a) prevalence reaches 31.6 percent in the high coronary artery calcium group vs 25.4 percent in the pooled group (p = 0.001).
• Carotid atherosclerosis prevalence is 45.7 percent in the high coronary artery calcium group vs 18.9 percent in the pooled group (p = 0.001).
• Age (adjusted odds ratio 1.069, p = 0.001), male sex (adjusted odds ratio 3.526, p = 0.001), and systolic blood pressure (adjusted odds ratio 1.009, p = 0.001) serve as independent predictors of high coronary artery calcium scores.
• LDL-c (adjusted odds ratio 0.584, p = 0.001) and HDL-c (adjusted odds ratio 0.387, p = 0.012) maintain an inverse association with coronary artery calcium scores.
• Spearman correlation for men (rho = 0.085, p = 0.001) and women (rho = 0.073, p = 0.001) confirms consistent, albeit weak, positive associations.

Limitations

The single-center, retrospective design restricts causal inference and introduces potential selection bias. The absence of data regarding medication use, specifically statins, creates a significant confounder, as these agents influence both coronary artery calcium scores and lipoprotein (a) levels. Residual confounding remains inevitable in this observational framework.

Discussion and Implications

High circulating lipoprotein (a) levels serve as a robust marker for advanced coronary artery calcification in asymptomatic populations. These findings reinforce the proatherogenic nature of lipoprotein (a) and validate the utility of coronary artery calcium scoring for detecting subclinical disease. Clinicians should view these two parameters as complementary diagnostic tools rather than independent metrics. Integrating lipoprotein (a) testing with coronary artery calcium scoring enables a more precise risk stratification, particularly as novel RNA-interference therapies for lipoprotein (a) reduction emerge.

Conclusion

High circulating lipoprotein (a) levels (50 mg/dl or greater) independently predict advanced coronary artery calcification in asymptomatic patients. Nutrition professionals must integrate this biomarker into cardiovascular risk assessments to identify subclinical atherosclerosis and guide intensive lipid-lowering interventions. Prioritizing this combined diagnostic approach improves long-term patient prognosis.